4.6 Article

Dissecting the role of the 3-phosphoinositide-dependent protein kinase-1 (PDK1) signalling pathways

期刊

CELL CYCLE
卷 7, 期 19, 页码 2978-2982

出版社

TAYLOR & FRANCIS INC
DOI: 10.4161/cc.7.19.6810

关键词

PDK1; knock-in mice; PKB/Akt; hyperinsulinemia; diabetes

资金

  1. Association for International Cancer Research
  2. Medical Research Council
  3. Moffat Charitable Trust
  4. AstraZeneca
  5. Boehringer-Ingelheim
  6. GlaxoSmithKline
  7. Merck Co., Inc.
  8. Merck KGaA
  9. Pfizer
  10. Spanish Ramon y Cajal Program
  11. Spanish Government Ministerio de Sanidad y Consumo [PI070101]
  12. Diabetes UK

向作者/读者索取更多资源

The 3-phosphoinositide-dependent protein kinase-1 (PDK1) mediates the cellular effect of insulin and growth factors by activating a group of kinases including PKB/Akt, S6K, RSK, SGK and PKC isoforms. PDK1 possesses two regulatory domains namely a Pleckstrin Homology (PH) domain that binds to the phosphatidylinositol 3,4,5-trisphosphate [PtdIns(3,4,5)P-3] second messenger, and a substrate binding site termed the PIF-pocket. Employing a combination of biochemical, structural and mouse knock-in approaches we have been able to define the roles that the regulatory domains on PDK1 play. We have established that binding of PDK1 to PtdIns(3,4,5) P3 is essential for efficient activation of PKB isoforms as well as for maintaining normal cell size and insulin sensitivity. In contrast, the PIF-substrate binding pocket of PDK1 is not required for PKB activation, but is necessary for PDK1 to activate all of its other substrates.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据